Expert Review - (2023) Volume 17, Issue 6
Received: 28-May-2023, Manuscript No. Iphsj-23-13895; Editor assigned: 30-May-2023, Pre QC No. Iphsj-23-13895 (PQ); Reviewed: 13-Jun-2023, QC No. Iphsj-23-13895; Revised: 16-Jun-2023, Manuscript No. Iphsj-23-13895(R); Published: 23-Jun-2023, DOI: 10.36648/1791- 809X.17.6.1035
Immunotherapy has emerged as a ground-breaking approach in the field of oncology, harnessing the power of the immune system to combat cancer. This review article provides an overview of immunotherapy and its different modalities, including immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, cancer vaccines, and cytokine therapy. We discuss the mechanisms of action, clinical applications, and recent advancements in each immunotherapeutic approach. Additionally, we explore the challenges and future prospects of immunotherapy, highlighting its potential in non-oncology fields such as autoimmune diseases and infectious diseases.
Immunotherapy; Cancer; Immune checkpoint inhibitors; CAR T-Cell Therapy; Cancer vaccines; Cytokine therapy; Immune system; Precision medicine
Immunotherapy has revolutionized cancer treatment by harnessing the body's immune system to selectively target and destroy cancer cells. Unlike traditional therapies, which directly target tumor cells, immunotherapy enhances the immune response [1], enabling the immune system to recognize and eliminate cancer cells more effectively. This review provides an indepth analysis of different immunotherapeutic approaches and their clinical applications, highlighting recent advancements and future prospects.
Immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) block inhibitory pathways, such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), to unleash the antitumor immune response. We discuss the mechanism of action, clinical efficacy, and safety profiles of ICIs, along with their approved indications in various cancer types. Furthermore, we delve into ongoing research to identify predictive biomarkers and optimize patient selection for ICI therapy [2-5].
Chimeric antigen receptor (CAR) T-cell therapy
CAR T-cell therapy involves modifying patients' T cells to express chimeric antigen receptors that specifically recognize and target tumor antigens. We explore the development of CAR T-cell therapy, its remarkable success in haematological malignancies, and on-going efforts to extend its application to solid tumors. Additionally, we discuss strategies to overcome challenges, such as cytokine release syndrome and neurotoxicity, associated with CAR T-cell therapy.
Cancer vaccines
Cancer vaccines stimulate the immune system to recognize and eliminate cancer cells by presenting tumor-specific antigens. We discuss different types of cancer vaccines, including peptide-based vaccines, dendritic cell vaccines, and viral vector-based vaccines. We highlight clinical trials evaluating the efficacy of cancer vaccines, their limitations, and on-going efforts to improve their effectiveness through combination therapies and personalized vaccine approaches [6].
Cytokine therapy
Cytokine therapy aims to modulate the immune response by administering cytokines, such as interleukins and interferon’s. We review the historical significance of cytokine therapy in cancer treatment, focusing on interleukin-2 (IL-2) and interferon-alpha (IFN-α). Additionally, we discuss the challenges associated with cytokine therapy, including toxicity profiles, and advancements in cytokine-based combination therapies.
Challenges and future prospects
We address the challenges and limitations of immunotherapy, including primary and acquired resistance, immune-related adverse events, and the high cost of treatment. Furthermore, we explore strategies to enhance the efficacy and safety of immunotherapy, such as combination approaches, patient selection criteria, and predictive biomarkers. We also discuss the potential of immunotherapy beyond cancer, including its application in autoimmune diseases, infectious diseases, and organ transplantation [7].
Immunotherapy is a ground-breaking approach to cancer treatment that has revolutionized the field of oncology and has the potential to transform the way we treat various other diseases as well. It harnesses the power of the body's immune system to recognize and attack cancer cells or other harmful cells in the body.
There are several different types of immunotherapy techniques that have been developed, each with its own mechanisms and applications. Here are some of the most prominent methods of immunotherapy:
Immune checkpoint inhibitors: Immune checkpoints are molecules on immune cells that prevent excessive immune responses. Cancer cells can exploit these checkpoints to evade detection by the immune system. Immune checkpoint inhibitors are drugs that block these checkpoints, allowing immune cells to recognize and attack cancer cells more effectively. Examples of immune checkpoint inhibitors include drugs like pembrolizumab and nivolumab, which target PD-1 and PD-L1 proteins.
CAR-T cell therapy: Chimeric Antigen Receptor T-cell (CAR-T) therapy involves modifying a patient's own T cells to express a specific receptor (CAR) that recognizes cancer cells. The modified CAR-T cells are then infused back into the patient's body, where they can target and destroy cancer cells. CAR-T cell therapy has shown remarkable success in treating certain types of blood cancers, such as leukaemia and lymphoma.
Tumor-infiltrating lymphocytes (TILs): TIL therapy involves isolating immune cells, particularly T cells, from a patient's tumor, expanding them in the laboratory, and then rein fusing them into the patient. These activated T cells can recognize and attack cancer cells more effectively [8].
Therapeutic vaccines: Therapeutic cancer vaccines aim to stimulate the immune system to recognize and destroy cancer cells. These vaccines are designed to either target specific tumor antigens or boost the overall immune response against cancer cells. They can be used alone or in combination with other immunotherapies.
Adoptive cell transfer: This technique involves extracting immune cells, such as T cells, from a patient, enhancing their activity in the laboratory, and then reintroducing them back into the patient's body. This approach can enhance the immune response against cancer cells and has shown promising results in certain types of cancers.
Monoclonal antibodies: Monoclonal antibodies are laboratoryproduced antibodies that can be designed to recognize specific molecules on cancer cells. These antibodies can directly target cancer cells, deliver drugs or radiation to cancer cells, or recruit other components of the immune system to destroy cancer cells [9].
Immunotherapy has indeed revolutionized cancer treatment and has the potential to transform the field of medicine beyond oncology. This innovative approach has provided new hope for patients and has demonstrated remarkable outcomes in certain types of cancer.
One of the key advantages of immunotherapy is its ability to harness the body's own immune system to target and eliminate cancer cells. Unlike traditional treatments like chemotherapy and radiation, which directly attack cancer cells but can also harm healthy cells, immunotherapy specifically focuses on enhancing the immune response against cancer cells while minimizing damage to healthy tissues. This targeted approach often leads to fewer side effects and improved quality of life for patients.
The success of immunotherapy can be seen in the treatment of advanced melanoma, where immune checkpoint inhibitors like pembrolizumab and nivolumab have significantly prolonged survival and improved long-term outcomes for patients. Similarly, in certain types of blood cancers, CAR-T cell therapy has produced remarkable results, with high response rates and durable remissions.
Moreover, immunotherapy is not limited to cancer treatment alone. The principles of harnessing the immune system can be applied to other diseases and conditions. On-going research is exploring the potential of immunotherapy in autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, where an overactive immune response damages healthy tissues. By modulating the immune system, it may be possible to restore balance and alleviate the symptoms of these conditions [10].
Immunotherapy is also being investigated for infectious diseases. For example, monoclonal antibodies have shown promise in treating viral infections like COVID-19 by neutralizing the virus and preventing its spread within the body. Additionally, therapeutic vaccines are being developed to combat infectious diseases such as HIV and malaria by boosting the immune response against these pathogens.
Beyond cancer and infectious diseases, there is growing interest in utilizing immunotherapy in other areas of medicine. Researchers are exploring its potential in treating neurodegenerative disorders like Alzheimer's disease, where immune dysfunction and inflammation play a role in disease progression. By targeting and modulating the immune system, it may be possible to slow down or even halt the neurodegenerative process.
Immunotherapy has transformed the landscape of cancer treatment, offering durable responses and improved survival outcomes for patients. The remarkable success of immune checkpoint inhibitors, CAR T-cell therapy, cancer vaccines, and cytokine therapy underscores the potential of harnessing the immune system.
Immunotherapy; Cancer; Immune checkpoint inhibitors; CAR T-Cell Therapy; Cancer vaccines; Cytokine therapy; Immune system; Precision medicine
Immunotherapy has revolutionized cancer treatment by harnessing the body's immune system to selectively target and destroy cancer cells. Unlike traditional therapies, which directly target tumor cells, immunotherapy enhances the immune response [1], enabling the immune system to recognize and eliminate cancer cells more effectively. This review provides an indepth analysis of different immunotherapeutic approaches and their clinical applications, highlighting recent advancements and future prospects.
Immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) block inhibitory pathways, such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), to unleash the antitumor immune response. We discuss the mechanism of action, clinical efficacy, and safety profiles of ICIs, along with their approved indications in various cancer types. Furthermore, we delve into ongoing research to identify predictive biomarkers and optimize patient selection for ICI therapy [2-5].
Chimeric antigen receptor (CAR) T-cell therapy
CAR T-cell therapy involves modifying patients' T cells to express chimeric antigen receptors that specifically recognize and target tumor antigens. We explore the development of CAR T-cell therapy, its remarkable success in haematological malignancies, and on-going efforts to extend its application to solid tumors. Additionally, we discuss strategies to overcome challenges, such as cytokine release syndrome and neurotoxicity, associated with CAR T-cell therapy.
Cancer vaccines
Cancer vaccines stimulate the immune system to recognize and eliminate cancer cells by presenting tumor-specific antigens. We discuss different types of cancer vaccines, including peptide-based vaccines, dendritic cell vaccines, and viral vector-based vaccines. We highlight clinical trials evaluating the efficacy of cancer vaccines, their limitations, and on-going efforts to improve their effectiveness through combination therapies and personalized vaccine approaches [6].
Cytokine therapy
Cytokine therapy aims to modulate the immune response by administering cytokines, such as interleukins and interferon’s. We review the historical significance of cytokine therapy in cancer treatment, focusing on interleukin-2 (IL-2) and interferon-alpha (IFN-α). Additionally, we discuss the challenges associated with cytokine therapy, including toxicity profiles, and advancements in cytokine-based combination therapies.
Challenges and future prospects
We address the challenges and limitations of immunotherapy, including primary and acquired resistance, immune-related adverse events, and the high cost of treatment. Furthermore, we explore strategies to enhance the efficacy and safety of immunotherapy, such as combination approaches, patient selection criteria, and predictive biomarkers. We also discuss the potential of immunotherapy beyond cancer, including its application in autoimmune diseases, infectious diseases, and organ transplantation [7].
Immunotherapy is a ground-breaking approach to cancer treatment that has revolutionized the field of oncology and has the potential to transform the way we treat various other diseases as well. It harnesses the power of the body's immune system to recognize and attack cancer cells or other harmful cells in the body.
There are several different types of immunotherapy techniques that have been developed, each with its own mechanisms and applications. Here are some of the most prominent methods of immunotherapy:
Immune checkpoint inhibitors: Immune checkpoints are molecules on immune cells that prevent excessive immune responses. Cancer cells can exploit these checkpoints to evade detection by the immune system. Immune checkpoint inhibitors are drugs that block these checkpoints, allowing immune cells to recognize and attack cancer cells more effectively. Examples of immune checkpoint inhibitors include drugs like pembrolizumab and nivolumab, which target PD-1 and PD-L1 proteins.
CAR-T cell therapy: Chimeric Antigen Receptor T-cell (CAR-T) therapy involves modifying a patient's own T cells to express a specific receptor (CAR) that recognizes cancer cells. The modified CAR-T cells are then infused back into the patient's body, where they can target and destroy cancer cells. CAR-T cell therapy has shown remarkable success in treating certain types of blood cancers, such as leukaemia and lymphoma.
Tumor-infiltrating lymphocytes (TILs): TIL therapy involves isolating immune cells, particularly T cells, from a patient's tumor, expanding them in the laboratory, and then rein fusing them into the patient. These activated T cells can recognize and attack cancer cells more effectively [8].
Therapeutic vaccines: Therapeutic cancer vaccines aim to stimulate the immune system to recognize and destroy cancer cells. These vaccines are designed to either target specific tumor antigens or boost the overall immune response against cancer cells. They can be used alone or in combination with other immunotherapies.
Adoptive cell transfer: This technique involves extracting immune cells, such as T cells, from a patient, enhancing their activity in the laboratory, and then reintroducing them back into the patient's body. This approach can enhance the immune response against cancer cells and has shown promising results in certain types of cancers.
Monoclonal antibodies: Monoclonal antibodies are laboratoryproduced antibodies that can be designed to recognize specific molecules on cancer cells. These antibodies can directly target cancer cells, deliver drugs or radiation to cancer cells, or recruit other components of the immune system to destroy cancer cells [9].
Immunotherapy has indeed revolutionized cancer treatment and has the potential to transform the field of medicine beyond oncology. This innovative approach has provided new hope for patients and has demonstrated remarkable outcomes in certain types of cancer.
One of the key advantages of immunotherapy is its ability to harness the body's own immune system to target and eliminate cancer cells. Unlike traditional treatments like chemotherapy and radiation, which directly attack cancer cells but can also harm healthy cells, immunotherapy specifically focuses on enhancing the immune response against cancer cells while minimizing damage to healthy tissues. This targeted approach often leads to fewer side effects and improved quality of life for patients.
The success of immunotherapy can be seen in the treatment of advanced melanoma, where immune checkpoint inhibitors like pembrolizumab and nivolumab have significantly prolonged survival and improved long-term outcomes for patients. Similarly, in certain types of blood cancers, CAR-T cell therapy has produced remarkable results, with high response rates and durable remissions.
Moreover, immunotherapy is not limited to cancer treatment alone. The principles of harnessing the immune system can be applied to other diseases and conditions. On-going research is exploring the potential of immunotherapy in autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, where an overactive immune response damages healthy tissues. By modulating the immune system, it may be possible to restore balance and alleviate the symptoms of these conditions [10].
Immunotherapy is also being investigated for infectious diseases. For example, monoclonal antibodies have shown promise in treating viral infections like COVID-19 by neutralizing the virus and preventing its spread within the body. Additionally, therapeutic vaccines are being developed to combat infectious diseases such as HIV and malaria by boosting the immune response against these pathogens.
Beyond cancer and infectious diseases, there is growing interest in utilizing immunotherapy in other areas of medicine. Researchers are exploring its potential in treating neurodegenerative disorders like Alzheimer's disease, where immune dysfunction and inflammation play a role in disease progression. By targeting and modulating the immune system, it may be possible to slow down or even halt the neurodegenerative process.
Immunotherapy has transformed the landscape of cancer treatment, offering durable responses and improved survival outcomes for patients. The remarkable success of immune checkpoint inhibitors, CAR T-cell therapy, cancer vaccines, and cytokine therapy underscores the potential of harnessing the immune system.
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Indexed at, Google Scholar, Crossref
Citation: Prazerekos P (2023) Immunotherapy as a Cancer Treatment Option in the Future. Health Sci J. Vol. 17 No. 6: 1035.
